MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

21.02 -0.20 (-0.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
PACIRA BIOSCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
6 Analysts Assess Pacira BioSciences: What You Need To Know ↗
 
Via Benzinga
News headline image
Decoding 6 Analyst Evaluations For Pacira BioSciences ↗
 
Via Benzinga
News headline image
Evaluating Pacira BioSciences: Insights From 8 Financial Analysts ↗
 
Via Benzinga
News headline image
Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
Company also reports preliminary unaudited 2024 revenue of $701.0 million 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Insights into Pacira BioSciences's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Expert Ratings For Pacira BioSciences ↗
 
Via Benzinga
News headline image
Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain ↗
Pacira launches a new iovera° Smart Tip for chronic back pain relief, offering an alternative to radiofrequency ablation with promising study results. 
Via Benzinga
News headline image
Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Lost Money on Pacira BioSciences, Inc.(PCRX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Via ACCESSWIRE
News headline image
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacira BioSciences, Inc. (PCRX) Regarding Possible Securities Fraud Violations
Via ACCESSWIRE
News headline image
Pacira BioSciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Pacira BioSciences, Inc. (PCRX)
Via ACCESSWIRE
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:PCRX. ↗
Investors should take note ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock that remains attractively priced. 
Via Chartmill
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting -- 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Third Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story